Several biomarkers have been described as risk predictors in HF, such as immune activation markers (e.g. Insulin-like growth factor 1 (IGF1), tumor necrosis factor (TNF), IL-6, CRP), natriuretic peptides (e.g., B-type natriuretic peptide (BNP) and N-terminal proBNP NT-proBNP), and high-sensitivity cardiac troponin [2]. This evidence concerns the gene IL6 and hydrops fetalis.